{"name":"Zheng Liu ENT","slug":"zheng-liu-ent","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Mometasone furoate as a nasal spray","genericName":"Mometasone furoate as a nasal spray","slug":"mometasone-furoate-as-a-nasal-spray","indication":"Allergic rhinitis","status":"phase_3"},{"name":"GR1802 injection-1","genericName":"GR1802 injection-1","slug":"gr1802-injection-1","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Mometasone furoate as a nasal spray","genericName":"Mometasone furoate as a nasal spray","slug":"mometasone-furoate-as-a-nasal-spray","phase":"phase_3","mechanism":"Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune and inflammatory responses.","indications":["Allergic rhinitis","Nasal polyps","Non-allergic rhinitis"],"catalyst":""},{"name":"GR1802 injection-1","genericName":"GR1802 injection-1","slug":"gr1802-injection-1","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5KdTRxT3pXR0pJYzlDNVRWeXJFNVEta3hTRU5wNzdadGsyMXZXSXBQS1pYU01LWWNVVE5pMmhlMjlmMFBhZUZuMVA2Tkx2S3hYZUc2TWhyUXJpZWFtSXFiZWdMcTQ2TFkwNHY1ZlJHQQ?oc=5","date":"2020-07-21","type":"pipeline","source":"Wiley Online Library","summary":"Divergent Total Synthesis of Euphoranginol C, Euphoranginone D, ent -Trachyloban-3β-ol, ent -Trachyloban-3-one, Excoecarin E, and ent -16α-Hydroxy-atisane-3-one - Wiley Online Library","headline":"Divergent Total Synthesis of Euphoranginol C, Euphoranginone D, ent -Trachyloban-3β-ol, ent -Trachyloban-3-one, Excoecar","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}